Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890746 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT01890746 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 148 participants.
The verdict
NCT01890746, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by antecedent malignant hematologic disorder and age.
Interventions
- DRUG Placebo
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2013-09-05 |
| Est. Completion | 2017-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01890746
The ClinicalTrials.gov registry entry for NCT01890746 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01890746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01890746 about?
NCT01890746 is a clinical study titled "A Safety and Efficacy Study of Eltrombopag in Subjects With AML". The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. A minimum of 120 e...
What is the current status of trial NCT01890746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2013-09-05. Estimated completion is 2017-01-25.
What interventions are being tested in trial NCT01890746?
The interventions under investigation include: Placebo (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01890746?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.